MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma

Y. Nezu, K. Hagiwara, Y. Yamamoto, T. Fujiwara, K. Matsuo, A. Yoshida, A. Kawai, T. Saito, T. Ochiya

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.

Original languageEnglish
Pages (from-to)6177-6188
Number of pages12
JournalOncogene
Volume35
Issue number48
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Myxoid Liposarcoma
Cellular Structures
MicroRNAs
Matrix Metalloproteinase 2
Neoplasms
Neoplasm Metastasis
Liposarcoma
Extracellular Matrix
thrombospondin 2
Population

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Nezu, Y., Hagiwara, K., Yamamoto, Y., Fujiwara, T., Matsuo, K., Yoshida, A., ... Ochiya, T. (2016). MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene, 35(48), 6177-6188. https://doi.org/10.1038/onc.2016.157

MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. / Nezu, Y.; Hagiwara, K.; Yamamoto, Y.; Fujiwara, T.; Matsuo, K.; Yoshida, A.; Kawai, A.; Saito, T.; Ochiya, T.

In: Oncogene, Vol. 35, No. 48, 01.12.2016, p. 6177-6188.

Research output: Contribution to journalArticle

Nezu, Y, Hagiwara, K, Yamamoto, Y, Fujiwara, T, Matsuo, K, Yoshida, A, Kawai, A, Saito, T & Ochiya, T 2016, 'MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma', Oncogene, vol. 35, no. 48, pp. 6177-6188. https://doi.org/10.1038/onc.2016.157
Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara T, Matsuo K, Yoshida A et al. MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene. 2016 Dec 1;35(48):6177-6188. https://doi.org/10.1038/onc.2016.157
Nezu, Y. ; Hagiwara, K. ; Yamamoto, Y. ; Fujiwara, T. ; Matsuo, K. ; Yoshida, A. ; Kawai, A. ; Saito, T. ; Ochiya, T. / MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. In: Oncogene. 2016 ; Vol. 35, No. 48. pp. 6177-6188.
@article{151c52964fc24599a0fef812bb36b059,
title = "MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma",
abstract = "Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.",
author = "Y. Nezu and K. Hagiwara and Y. Yamamoto and T. Fujiwara and K. Matsuo and A. Yoshida and A. Kawai and T. Saito and T. Ochiya",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/onc.2016.157",
language = "English",
volume = "35",
pages = "6177--6188",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "48",

}

TY - JOUR

T1 - MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma

AU - Nezu, Y.

AU - Hagiwara, K.

AU - Yamamoto, Y.

AU - Fujiwara, T.

AU - Matsuo, K.

AU - Yoshida, A.

AU - Kawai, A.

AU - Saito, T.

AU - Ochiya, T.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.

AB - Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.

UR - http://www.scopus.com/inward/record.url?scp=84966521983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966521983&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.157

DO - 10.1038/onc.2016.157

M3 - Article

VL - 35

SP - 6177

EP - 6188

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 48

ER -